Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Operating Expenses (2016 - 2025)

Ocular Therapeutix has reported Operating Expenses over the past 13 years, most recently at $83.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $83.0 million for Q4 2025, up 22.69% from a year ago — trailing twelve months through Dec 2025 was $322.0 million (up 36.71% YoY), and the annual figure for FY2025 was $322.0 million, up 36.71%.
  • Operating Expenses for Q4 2025 was $83.0 million at Ocular Therapeutix, roughly flat from $83.2 million in the prior quarter.
  • Over the last five years, Operating Expenses for OCUL hit a ceiling of $83.2 million in Q3 2025 and a floor of $27.6 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $35.3 million (2023), compared with a mean of $47.5 million.
  • Biggest five-year swings in Operating Expenses: increased 0.73% in 2022 and later soared 94.14% in 2024.
  • Ocular Therapeutix's Operating Expenses stood at $30.4 million in 2021, then increased by 10.14% to $33.4 million in 2022, then increased by 4.23% to $34.9 million in 2023, then skyrocketed by 94.14% to $67.7 million in 2024, then grew by 22.69% to $83.0 million in 2025.
  • The last three reported values for Operating Expenses were $83.0 million (Q4 2025), $83.2 million (Q3 2025), and $81.1 million (Q2 2025) per Business Quant data.